SV1997000032A - Virosomas cationicos como sistema de transferencia para material genetico. - Google Patents

Virosomas cationicos como sistema de transferencia para material genetico.

Info

Publication number
SV1997000032A
SV1997000032A SV1997000032A SV1997000032A SV1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A SV 1997000032 A SV1997000032 A SV 1997000032A
Authority
SV
El Salvador
Prior art keywords
virosomes
transfer system
genetic material
cationic virosomes
membrane
Prior art date
Application number
SV1997000032A
Other languages
English (en)
Spanish (es)
Inventor
Klein Peter
Gluck Reinhard
Walti Ernst Rudolf
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of SV1997000032A publication Critical patent/SV1997000032A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SV1997000032A 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico. SV1997000032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (1)

Publication Number Publication Date
SV1997000032A true SV1997000032A (es) 1998-03-27

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000032A SV1997000032A (es) 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico.

Country Status (28)

Country Link
US (1) US6210708B1 (https=)
EP (1) EP0902682A2 (https=)
JP (1) JP2000509404A (https=)
KR (1) KR100536983B1 (https=)
CN (1) CN1271992C (https=)
AR (1) AR007054A1 (https=)
AU (1) AU710170B2 (https=)
BG (1) BG102880A (https=)
BR (1) BR9709224A (https=)
CA (1) CA2253561A1 (https=)
CO (1) CO4600638A1 (https=)
CZ (1) CZ299809B6 (https=)
EA (1) EA003130B1 (https=)
GT (1) GT199700058A (https=)
HR (1) HRP970234B1 (https=)
HU (1) HUP9901790A3 (https=)
ID (1) ID17934A (https=)
NO (1) NO327726B1 (https=)
NZ (1) NZ332666A (https=)
OA (1) OA10916A (https=)
PA (1) PA8429201A1 (https=)
PE (1) PE65198A1 (https=)
PL (1) PL199201B1 (https=)
SK (1) SK152698A3 (https=)
SV (1) SV1997000032A (https=)
TN (1) TNSN97080A1 (https=)
WO (1) WO1997041834A1 (https=)
ZA (1) ZA973885B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU9224398A (en) * 1997-09-08 1999-03-29 Promega Corporation Method of (in vivo) transformation utilizing lipid vehicles
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
HUP0202809A2 (hu) * 1999-10-08 2002-12-28 Nika Health Products Limited Kationos DOSPER-viroszómák
ES2202218T3 (es) * 1999-12-17 2004-04-01 Schott Glas Capsula fulminante activable inductivamente para sistemas de retencion de pasajeros y circuito de prueba para esta capsula fulminante.
EP1252897A4 (en) * 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
EP1409653A4 (en) * 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
PL377161A1 (pl) * 2002-11-21 2006-01-23 Pevion Biotech Ltd. Wysoce efektywne pęcherzyki fuzogenne, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierające te pęcherzyki
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
EP1687017B1 (en) 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 f/hn 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
WO2018060213A1 (en) 2016-09-27 2018-04-05 Camurus Ab Formulations containing a somatostatin receptor agonist
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
DK0538437T3 (da) * 1991-05-08 2000-02-07 Schweiz Serum & Impfinst Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
WO1993014744A1 (en) 1992-02-04 1993-08-05 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
ATE223701T1 (de) * 1994-05-31 2002-09-15 Inex Pharmaceutical Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
NZ332666A (en) 2000-05-26
CN1271992C (zh) 2006-08-30
CZ299809B6 (cs) 2008-12-03
BR9709224A (pt) 1999-08-10
ID17934A (id) 1998-02-12
CA2253561A1 (en) 1997-11-13
PL329853A1 (en) 1999-04-12
AU2776697A (en) 1997-11-26
NO985137L (no) 1999-01-04
HRP970234B1 (en) 2002-04-30
AU710170B2 (en) 1999-09-16
EP0902682A2 (en) 1999-03-24
CN1225007A (zh) 1999-08-04
PL199201B1 (pl) 2008-08-29
HUP9901790A2 (hu) 1999-08-30
PE65198A1 (es) 1998-10-16
ZA973885B (en) 1998-11-06
HUP9901790A3 (en) 2010-11-29
CZ361498A3 (cs) 1999-03-17
JP2000509404A (ja) 2000-07-25
NO327726B1 (no) 2009-09-14
HRP970234A2 (en) 1998-06-30
TNSN97080A1 (fr) 2005-03-15
NO985137D0 (no) 1998-11-04
PA8429201A1 (es) 2000-05-24
EA003130B1 (ru) 2003-02-27
WO1997041834A1 (en) 1997-11-13
US6210708B1 (en) 2001-04-03
GT199700058A (es) 1998-10-29
EA199800992A1 (ru) 1999-06-24
KR100536983B1 (ko) 2006-06-29
OA10916A (en) 2003-02-21
CO4600638A1 (es) 1998-05-08
BG102880A (en) 1999-05-31
SK152698A3 (en) 1999-05-07
KR20000010780A (ko) 2000-02-25
AR007054A1 (es) 1999-10-13

Similar Documents

Publication Publication Date Title
SV1997000032A (es) Virosomas cationicos como sistema de transferencia para material genetico.
CO5021164A1 (es) Genes de elongasa y sus usos
ATE254664T1 (de) Renilla luciferase und green fluorescent protein fusionsgene
ES2119250T3 (es) Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos.
ES2146775T3 (es) Tratamiento de terapia genica de enfermedades del sistema nervioso central (snc) mediante un principio activo especifico de las celulas e independiente del ciclo celular.
DE69027526D1 (de) Herstellung von proteinen mittels homologer rekombination
Labat-Robert et al. Fibronectin-like protein in Porifera: its role in cell aggregation.
PT1077072E (pt) Processo in vitro para produzir uma protese homologa de valvula cardiaca ou uma protese homologa de vaso sanguineo
PT980263E (pt) Produto de combinacao que associa um acido nucleico a uma substancia desorganizadora da matriz extracelular para terapia genetica
BR9807966A (pt) ácido nucleico isolado, cassete e vetor de expressão, célula, planta, progênie, semente, processos para produzir uma planta, pra induzir a produção de pelo menos um dentre ácido gama linolênico (gla) ou ácido octadecatetraeÈnico (ota) em uma planta deficiente ou com falta de gla, para diminuir a produção de um gene de sìntese de ácido graxo ou metabolismo de lipìdeo em uma planta, e, para co-suprimir um gene de sìntese de ácido graxo ou metabolismo de lipìdeos nativo em uma planta.
ATE211166T1 (de) Zellkulturmatrix und biologisch abbaubare dreidimensionale matrix auf hyaluronsäurederivatbasis
MX9207397A (es) Recipientes para cultivo de celulas que tienen hileras interiores y metodo para cultivar celulas en los mismos.
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
EP1446489A4 (en) INTEGRATED MINI CELLS AS VECTORS FOR DNA TRANSFER AND GENE THERAPY IN VITRO AND IN VIVO
BR9908499A (pt) Linhagens celulares embrionárias ousemelhantes a tronco produzidas portransplante nuclear de espécies cruzado
Higashi et al. A novel transfection method for mammalian cells using calcium alginate microbeads
ES2165050T3 (es) Nuevos derivados cationicos de colesterilo que contienen grupos polares ciclicos.
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
EP0808364A4 (en) Human pancreatic cell lines: developments and uses
ATE111516T1 (de) Invasive mikroorganismen.
Zhu et al. Efficient establishment of Guangxi Bama mini-pig transgenic fibroblasts via Xfect polymer transfection
ATE292675T1 (de) Tetrahydropyrimidin-dioxygenase-gen, dadurch kodierte polypeptide und verfahren zur deren herstellung
UY26317A1 (es) Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
Mubarik et al. Mitochondrial and photosynthetic therapy: A crucial strategy for remodeling cellular metabolic function
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena